News & Insights

Latest updates from ACESO Therapeutics

Follow our progress as we advance our approach designed to restore what Cystic Fibrosis takes away.

Featured

San Diego convention Center: June 22 – 25 – 2026

We are preparing to raise funds, with part already secured, to complete our regulatory preclinical studies, with CTA submission targeted for late 2027.

All news

Research, milestones & updates

Browse the latest from ACESO across company news, research, publications, and industry events.

SATT AxLR enters the capital of Aceso Therapeutics and supports the development of ACT-101 for cystic fibrosis

Montpellier, March 2026 — Aceso Therapeutics announces the entry of SATT AxLR into its capital, marking a new milestone in the development of its biotech focused on innovative therapies for

European Young Investigators Meeting (EYIM) – March 2026

European Young Investigators Meeting (EYIM) - 2026

Collaboration between Aceso Therapeutics and the University of Montpellier to develop a new therapy for cystic fibrosis

Montpellier, February 2026 — Aceso Therapeutics and the Université de Montpellier, in collaboration with the PhyMedExp laboratories, announce a research collaboration dedicated to the development of new therapeutic approaches for

ACESO Therapeutics announces progress in advancing its cystic fibrosis therapeutic pipeline

ACESO continues to build a scientific foundation for a new generation of cystic fibrosis therapy focused on patients underserved by current treatment options. ACESO Therapeutics is advancing a therapeutic strategy

Deeptech Connect 2025

AcesoTherapeutics will be attending Deeptech Connect on November 4, 2025 – the flagship event organized by the #SATT network, showcasing the best of French #Deeptech startups. 🎯 A great opportunity to discover an investment opportunity in our novel cystic

Innovation Award 2025

🎉 Congratulations to Magali Taulan-Cadars and Prisca Boisguerin for winning the 2025 Innovation « Coup de cœur » Award with their StabCFTR project, aiming to improve care for cystic fibrosis

EUROPEAN CYSTIC FIBROSIS SOCIETY 2025

 CFTR stabilizers as therapeutic tools in cystic fibrosis

SATT AxLR enters the capital of Aceso Therapeutics and supports the development of ACT-101 for cystic fibrosis

Montpellier, March 2026 — Aceso Therapeutics announces the entry of SATT AxLR into its capital, marking a new milestone in the development of its biotech focused on innovative therapies for

Collaboration between Aceso Therapeutics and the University of Montpellier to develop a new therapy for cystic fibrosis

Montpellier, February 2026 — Aceso Therapeutics and the Université de Montpellier, in collaboration with the PhyMedExp laboratories, announce a research collaboration dedicated to the development of new therapeutic approaches for

ACESO Therapeutics announces progress in advancing its cystic fibrosis therapeutic pipeline

ACESO continues to build a scientific foundation for a new generation of cystic fibrosis therapy focused on patients underserved by current treatment options. ACESO Therapeutics is advancing a therapeutic strategy

Innovation Award 2025

🎉 Congratulations to Magali Taulan-Cadars and Prisca Boisguerin for winning the 2025 Innovation « Coup de cœur » Award with their StabCFTR project, aiming to improve care for cystic fibrosis

European Young Investigators Meeting (EYIM) – March 2026

European Young Investigators Meeting (EYIM) - 2026

EUROPEAN CYSTIC FIBROSIS SOCIETY 2025

 CFTR stabilizers as therapeutic tools in cystic fibrosis

San Diego convention Center: June 22 – 25 – 2026

We are preparing to raise funds, with part already secured, to complete our regulatory preclinical studies, with CTA submission targeted for late 2027.

Deeptech Connect 2025

AcesoTherapeutics will be attending Deeptech Connect on November 4, 2025 – the flagship event organized by the #SATT network, showcasing the best of French #Deeptech startups. 🎯 A great opportunity to discover an investment opportunity in our novel cystic

Stay in the loop

Stay informed as we advance the science.

Receive selected company updates, research milestones, and ACESO Therapeutics news.

    Stay in the loop

    Get in touch

    Stay informed as we advance the science.

    Partner with us to redefine cystic fibrosis care.

    Receive selected company updates, research milestones, and ACESO Therapeutics news.

    Whether you’re an investor, strategic partner, or member of the scientific community — we’d be glad to talk.

    Email

    Headquarters

    Montpellier, France